Shopping Cart
- Remove All
- Your shopping cart is currently empty
ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.444 € | 6-8 weeks | |
50 mg | 1.881 € | 6-8 weeks | |
100 mg | 2.375 € | 6-8 weeks |
Description | ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. |
Molecular Weight | 572.6 |
Formula | C24H31F3N6O5S |
Cas No. | 220519-07-3 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.